Literature DB >> 2242757

Glycosylation of IgG, immune complexes and IgG subclasses in the MRL-lpr/lpr mouse model of rheumatoid arthritis.

A Bond1, A Cooke, F C Hay.   

Abstract

The MRL-lpr/lpr (MRL/lpr) mouse spontaneously develops a disease syndrome which, in many respects, is similar to human rheumatoid arthritis. These mice developed joint inflammation, circulating rheumatoid factors and immune complexes. We now show that the parallel with human disease extends to a glycosylation defect which is observed on IgG from rheumatoid arthritis patients. Using the lectins ricin and Bandeiraea simplicifolia II we have found that terminal N-acetylglucosamine is clearly raised in MRL/lpr IgG. Increased exposure of galactose was also detected, indicating that a second glycosylation site must be present on these molecules. Polyethylene glycol-precipitated IgG complexes bound significantly more of each lectin than did free IgG, indicating that the changes in glycosylation were associated with complex formation. The sugar abnormality was most marked in the IgG2a/IgG3 fraction from protein A IgG subclass chromatography. Our results suggest that the IgG glycosylation defect seen in rheumatoid arthritis is apparent in the MRL/lpr mouse and may contribute, through complex formation, to the pathological processes in the rheumatoid syndrome.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2242757     DOI: 10.1002/eji.1830201011

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  17 in total

1.  Second Jenner international glycoimmunology meeting.

Authors: 
Journal:  Ann Rheum Dis       Date:  1992-11       Impact factor: 19.103

Review 2.  The role of sialic acid as a modulator of the anti-inflammatory activity of IgG.

Authors:  Sybille Böhm; Inessa Schwab; Anja Lux; Falk Nimmerjahn
Journal:  Semin Immunopathol       Date:  2012-03-22       Impact factor: 9.623

Review 3.  Mechanisms of IVIG efficacy in chronic inflammatory demyelinating polyneuropathy.

Authors:  Björn Tackenberg; Falk Nimmerjahn; Jan D Lünemann
Journal:  J Clin Immunol       Date:  2010-05       Impact factor: 8.317

Review 4.  Activating and inhibitory FcgammaRs in autoimmune disorders.

Authors:  Falk Nimmerjahn
Journal:  Springer Semin Immunopathol       Date:  2006-10-01

5.  Agalactosylated IgG antibodies depend on cellular Fc receptors for in vivo activity.

Authors:  Falk Nimmerjahn; Robert M Anthony; Jeffrey V Ravetch
Journal:  Proc Natl Acad Sci U S A       Date:  2007-05-07       Impact factor: 11.205

Review 6.  The importance of oligosaccharides to rheumatic disease: a personal perspective.

Authors:  J S Axford
Journal:  Glycoconj J       Date:  1997-11       Impact factor: 2.916

Review 7.  Intravenous immunoglobulin therapy: how does IgG modulate the immune system?

Authors:  Inessa Schwab; Falk Nimmerjahn
Journal:  Nat Rev Immunol       Date:  2013-02-15       Impact factor: 53.106

8.  The history of IgG glycosylation and where we are now.

Authors:  Brian A Cobb
Journal:  Glycobiology       Date:  2020-03-20       Impact factor: 4.313

9.  Does it take sugar? A clinical role for measuring the glycosylation of IgG?

Authors:  A Rahman; D Isenberg
Journal:  Ann Rheum Dis       Date:  1995-09       Impact factor: 19.103

Review 10.  Heat-shock proteins and autoimmunity in humans.

Authors:  P Res; J Thole; R de Vries
Journal:  Springer Semin Immunopathol       Date:  1991
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.